OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA; EXPERIENCE FROM A SINGLE CENTER IN SAUDI ARABIA
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.240_2631
Abstract: del17p – 5.6% (9/159); 1p32/1q21 amp/del – 12% (19/159); hypodiploidy – 3.1% (5/159); hyperdiploidy – 1.25% (2/159); del5q – 0,6% (1/159); other – not found. Combination two aberrations was discovered in 11.9% (19/159) patients, complex… read more here.
Keywords: risk; risk msmart; median pfs; complex abnormalities ... See more keywords
938PDPrognostic relevance of immune-related gene expression signatures (irGES) in patients (pts) with ovarian clear cell carcinomas (OCCC)
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx372.008
Abstract: Results: Total of 74/84 samples were successfully profiled. Median age at diagnosis was 53 yrs. 41 (55.4%) were stage 1, 7 (9.5%) stage 2, 24 (32.4%) Stage3, 2 (2.7%) stage 4. 64/74 (86.5%) of pts… read more here.
Keywords: cell; median pfs; stage pts; expression ... See more keywords
Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration-approved solid tumor therapies, 1995-2021.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.28.11.1219
Abstract: BACKGROUND: Many cancer therapies are now approved based on surrogate endpoints such as progression-free survival (PFS) to ensure that patients have speedy access to life-saving cancer medicines. However, the link between surrogate endpoints and overall… read more here.
Keywords: oncology; median pfs; pfs; 1995 2021 ... See more keywords
Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of thoracic disease"
DOI: 10.21037/jtd-20-2855
Abstract: Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of anlotinib… read more here.
Keywords: median pfs; advanced nsclc; lung cancer; patients advanced ... See more keywords
Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.654020
Abstract: Background Hepatocellular carcinoma (HCC) is the third most fatal cancer, with a 5-year survival rate of 18%. Standard frontline-therapy is multikinase inhibitors (MKIs), but accessibility is still limited, particularly in developing countries. This network meta-analysis… read more here.
Keywords: hepatocellular carcinoma; pfs months; median pfs; multikinase inhibitors ... See more keywords
Eighteen years’ experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1014455
Abstract: Introduction The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150–300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed… read more here.
Keywords: median pfs; glioblastoma; treated ttfields; newly diagnosed ... See more keywords